Vanguard Global Advisers’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.29M Buy
60,216
+3,274
+6% +$138K ﹤0.01% 1161
2026
Q2
$2.68M Buy
56,942
+8,898
+19% +$220K ﹤0.01% 1080
2026
Q1
$908K Buy
+48,044
New +$815K ﹤0.01% 1710

Other funds holding DFTX

Vanguard Global Advisers's DFTX Position: Q3 2026 in Review

Vanguard Global Advisers increased its Definium Therapeutics (DFTX) stake by 5.7% in Q3 2026, buying an estimated $138K and bringing the position to 60,216 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1161.

Vanguard Global Advisers first reported a position in DFTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.68M in Q2 2026. 353 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Vanguard Global Advisers held 60,216 shares of Definium Therapeutics worth $2.29M as of Q3 2026.
  • Vanguard Global Advisers bought 3,274 Definium Therapeutics shares in Q3 2026, an estimated $138K.
  • Definium Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1161 holding.
  • Vanguard Global Advisers first reported a position in Definium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Definium Therapeutics position peaked at $2.68M in Q2 2026.
  • 353 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.